Comprehensive Bleeding Disorder Center, Peoria, Illinois   Report issue

Academic/Hospital Phase 3
Founded: Peoria IL United States
Status: Acquired by Bleeding and Clotting Disorders Institute (2010)

Organization Overview

First Clinical Trial
2001
NCT00157053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Comprehensive Bleeding Disorder Center, Peoria, Illinois, USA

Active Ingredients

Drugs in Phase 3 Trials (1)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1